secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001193125-25-284633
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q4 net loss $0.87/sh, revenue $15.1M; cash $188.9M; RSV data positive, STAT6 candidate selected
--------------------------------------------------------------------------------

- Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.
- Total revenue $15.1M from MAVYRET royalties; FY 2025 revenue $65.3M vs $67.6M prior year.
- Ending cash $188.9M; plus $74.8M gross from Oct 2025 offering; runway into FY2029.
- Zelicapavir Phase 2b in high-risk RSV adults met secondary endpoints; 2.2-day symptom resolution improvement.
- Nominated EPS-3903 (STAT6 inhibitor) with >90% pSTAT6 suppression; IND target H2 2026; EDP-978 IND Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/0001193125-25-284633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/enta-20251117.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-284633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer